Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509210 | 0.92 | CA1 (0.43) | CYP1A2CYP2A6CA2CA1CA9 | |
| SCHEMBL4496657 | 0.84 | CA2 (0.40) | CA2CA1CA9LMNACA12 | |
| SCHEMBL4509260 | 0.84 | HTT (0.43) | CA2CA1CA9LMNACA12 | |
| SCHEMBL4510627 | 0.84 | ESR1 (0.39) | CYP1A2CA2CA1CA9LMNA | |
| SCHEMBL4506325 | 0.84 | PTGES (0.56) | CA2CA1CA9CA12PTGES | |
| SCHEMBL4507193 | 0.82 | CA1 (0.41) | CA2CA1CA9LMNACA12 | |
| SCHEMBL4506268 | 0.81 | CA1 (0.44) | CYP1A2CA2CA1CA9LMNA | |
| SCHEMBL4496636 | 0.79 | MEN1 (0.36) | CA2CA1CA9LMNACA12 | |
| SCHEMBL4500899 | 0.78 | PTGES (0.46) | CA2CA1CA9LMNACA12 | |
| SCHEMBL4512410 | 0.77 | CA2 (0.41) | CYP1A2CA2CA1CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | AREG, PRSS12, CXCL8 | CYP1A2 1161/4885CYP2A6 1210/4885CA2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.